Abstract:Background and purpose:Inhibitor of apoptosis-stimulating protein of p53 (iASPP) is one of the ASPP family. It binds to p53 to inhibit the transcriptional activity of p53-target genes and cell apoptosis, which is asso-ciated with tumor formation. Previously, we found a new subtype of iASPP, iASPP splice variant (iASPP-SV), which is a nuclear protein containing 407 amino acid residues and can bind to p53, inhibiting p53 transcriptional activity. However, the relationship of iASPP-SV and breast cancer is still obscure. Therefore, the purpose of this research was to study the role of iASPP-SV on breast cancer tumorigenesis and progression.Methods:5’-rapid ampliifcation of cDNA ends (RACE) was used to identify the 5’-end of iASPP-SV mRNA in MCF-7 cells. HEK 293 cells were transfected with pFLAG-iASPP-SV and pFLAG-iASPP (828). Then Western blot was used to identify whether endogenous iASPP-SV was expressed in HEK 293 cells and 8 types of human tumor cell lines. This study established the stable clones of NIH 3T3 expressing FLAG-iASPP-SV and FLAG-iASPP (828). Cell proliferation assay, colony formation and soft agar colony formation assay were used to identify whether iASPP-SV and iASPP (828) can promote cell proliferation and iASPP-SV is an oncogene. Real-time lfuorescent quantitative polymerase chain reactive (RTFQ-PCR) was used to de-tect the levels of iASPP-SV and iASPP (828) mRNA in primary breast cancers. Luciferase assays were used to identify the relationships between iASPP-SV, iASPP (828), p53 and NF-κB p65.Results:The study identiifed that iASPP-SV was encoded by previously reported NF-κB p65 subunit (RelA)-associated inhibitor (RAI), and endogenously expressed in many human cancer cell lines. Analysis of cell proliferation, colony formation assay and soft agar assay for colony formation identiifed that similarly to iASPP (828), iASPP-SV promoted tumor cell proliferation and acted as an onco-gene. RTFQ-PCR result showed that the median values of iASPP-SV and iASPP (828) in breast cancers with wild-type p53 were more signiifcantly over-expressed than those of mutant p53. Luciferase assays showed that iASPP-SV and iASPP (828) could suppress NF-κB p65 transcriptional activity. Thus iASPP family may participate in the regulation of p53 and NF-κB activity, which imply that iASPP perhaps shows pro- or anti-survival activities when it interacts with different proteins.Conclusion:These ifndings indicate that iASPP-SV may be a potential target for breast cancer thera-py.

A Previously Identified Apoptosis Inhibitor Iaspp Confers Resistance to Chemotherapeutic Drugs by Suppressing Senescence in Cancer Cells

Blocking iASPP/Nrf2/M-CSF axis improves anti-cancer effect of chemotherapy-induced senescence by attenuating M2 polarization

iASPP Is an Antioxidative Factor and Drives Cancer Growth and Drug Resistance by Competing with Nrf2 for Keap1 Binding

Iasppsv Antagonizes Apoptosis Induced by Chemotherapeutic Agents in MCF-7 Cells and Mouse Thymocytes

Nuclear Iaspp Determines Cell Fate by Selectively Inhibiting Either P53 or NF-κB

iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe.

Effects Of Iaspp On Paclitaxel-Mediated Mitotic Catastrophe And Chemoresistance In Ovarian Cancers

Oncogene Iaspp Enhances Self‐renewal of Hematopoietic Stem Cells and Facilitates Their Resistance to Chemotherapy and Irradiation

iASPP-SV, an Important iASPP isoform, participated in breast tumorigenesis/progression

Downregulation of Iaspp Expression Suppresses Proliferation, Invasion and Increases Chemosensitivity to Paclitaxel of Head and Neck Squamous Cell Carcinoma in Vitro.

Reactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumors

Iaspp-Sv, As an Oncogene, Participates in Breast Tumorigenesis and Progression

Overcoming the senescence‐associated secretory phenotype (SASP): a complex mechanism of resistance in the treatment of cancer

iASPP suppression mediates terminal UPR and improves BRAF-inhibitor sensitivity of colon cancers

iASPP suppresses Gp78-mediated TMCO1 degradation to maintain Ca<SUP>2+</SUP> homeostasis and control tumor growth and drug resistance

Iaspp Oncoprotein is A Key Inhibitor of P53 Conserved from Worm to Human

An iASPP‐derived short peptide restores p53‐mediated cell death in cancers with wild‐type p53

Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD‐L1)‐mediated immunosuppression

Iaspp Facilitates Tumor Growth by Promoting Mtor-Dependent Autophagy in Human Non-Small-cell Lung Cancer.

EGR-1/ASPP1 inter-regulatory loop promotes apoptosis by inhibiting cyto-protective autophagy

iASPP on apoptosis in breast cancer cells which expressed wild type p53